Cargando…

Atropisomerism in the Pharmaceutically Relevant Realm

[Image: see text] Atropisomerism is a conformational chirality that occurs when there is hindered rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in many other pharmaceutically relevant scaffolds including heterobiaryls, benzamides, diarylamines, and anilides....

Descripción completa

Detalles Bibliográficos
Autores principales: Basilaia, Mariami, Chen, Matthew H., Secka, Jim, Gustafson, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583608/
https://www.ncbi.nlm.nih.gov/pubmed/36153960
http://dx.doi.org/10.1021/acs.accounts.2c00500
_version_ 1784813108683866112
author Basilaia, Mariami
Chen, Matthew H.
Secka, Jim
Gustafson, Jeffrey L.
author_facet Basilaia, Mariami
Chen, Matthew H.
Secka, Jim
Gustafson, Jeffrey L.
author_sort Basilaia, Mariami
collection PubMed
description [Image: see text] Atropisomerism is a conformational chirality that occurs when there is hindered rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in many other pharmaceutically relevant scaffolds including heterobiaryls, benzamides, diarylamines, and anilides. As bond rotation leads to racemization, atropisomers span the gamut of stereochemical stability. LaPlante has classified atropisomers based on their half-life of racemization at 37 °C: class 1 (t(1/2) < 60 s), class 2 (60 s < t(1/2) < 4.5 years), and class 3 (t(1/2) > 4.5 years). In general, class-3 atropisomers are considered to be suitable for drug development. There are currently four FDA-approved drugs that exist as stable atropisomers, and many others are in clinical trials or have recently appeared in the drug discovery literature. Class-1 atropisomers are more prevalent, with ∼30% of recent FDA-approved small molecules possessing at least one class-1 axis. While class-1 atropisomers do not possess the requisite stereochemical stability to meet the classical definition of atropisomerism, they often bind a given target in a specific set of chiral conformations. Over the past decade, our laboratory has embarked on a research program aimed at leveraging atropisomerism as a design feature to improve the target selectivity of promiscuous lead compounds. Our studies initially focused on introducing class-3 atropisomerism into promiscuous kinase inhibitors, resulting in a proof of principle in which the different atropisomers of a compound can have different selectivity profiles with potentially improved target selectivity. This inspired a careful analysis of the binding conformations of diverse ligands bound to different target proteins, resulting in the realization that the sampled dihedral conformations about a prospective atropisomeric axis played a key role in target binding and that preorganizing the prospective atropisomeric axis into a desired target’s preferred conformational range can lead to large gains in target selectivity. As atropisomerism is becoming more prevalent in modern drug discovery, there is an increasing need for strategies for atropisomerically pure samples of pharmaceutical compounds. This has led us and other groups to develop catalytic atroposelective methodologies toward pharmaceutically privileged scaffolds. Our laboratory has contributed examples of atroposelective methodologies toward heterobiaryl systems while also exploring the chirality of less-studied atropisomers such as diarylamines and related scaffolds. This Account will detail recent encounters with atropisomerism in medicinal chemistry and how atropisomerism has transitioned from a “lurking menace” into a leverageable design strategy in order to modulate various properties of biologically active small molecules. This Account will also discuss recent advances in atroposelective synthesis, with a focus on methodologies toward pharmaceutically privileged scaffolds. We predict that a better understanding of the effects of conformational restriction about a prospective atropisomeric axis on target binding will empower chemists to rapidly “program” the selectivity of a lead molecule toward a desired target.
format Online
Article
Text
id pubmed-9583608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-95836082022-10-21 Atropisomerism in the Pharmaceutically Relevant Realm Basilaia, Mariami Chen, Matthew H. Secka, Jim Gustafson, Jeffrey L. Acc Chem Res [Image: see text] Atropisomerism is a conformational chirality that occurs when there is hindered rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in many other pharmaceutically relevant scaffolds including heterobiaryls, benzamides, diarylamines, and anilides. As bond rotation leads to racemization, atropisomers span the gamut of stereochemical stability. LaPlante has classified atropisomers based on their half-life of racemization at 37 °C: class 1 (t(1/2) < 60 s), class 2 (60 s < t(1/2) < 4.5 years), and class 3 (t(1/2) > 4.5 years). In general, class-3 atropisomers are considered to be suitable for drug development. There are currently four FDA-approved drugs that exist as stable atropisomers, and many others are in clinical trials or have recently appeared in the drug discovery literature. Class-1 atropisomers are more prevalent, with ∼30% of recent FDA-approved small molecules possessing at least one class-1 axis. While class-1 atropisomers do not possess the requisite stereochemical stability to meet the classical definition of atropisomerism, they often bind a given target in a specific set of chiral conformations. Over the past decade, our laboratory has embarked on a research program aimed at leveraging atropisomerism as a design feature to improve the target selectivity of promiscuous lead compounds. Our studies initially focused on introducing class-3 atropisomerism into promiscuous kinase inhibitors, resulting in a proof of principle in which the different atropisomers of a compound can have different selectivity profiles with potentially improved target selectivity. This inspired a careful analysis of the binding conformations of diverse ligands bound to different target proteins, resulting in the realization that the sampled dihedral conformations about a prospective atropisomeric axis played a key role in target binding and that preorganizing the prospective atropisomeric axis into a desired target’s preferred conformational range can lead to large gains in target selectivity. As atropisomerism is becoming more prevalent in modern drug discovery, there is an increasing need for strategies for atropisomerically pure samples of pharmaceutical compounds. This has led us and other groups to develop catalytic atroposelective methodologies toward pharmaceutically privileged scaffolds. Our laboratory has contributed examples of atroposelective methodologies toward heterobiaryl systems while also exploring the chirality of less-studied atropisomers such as diarylamines and related scaffolds. This Account will detail recent encounters with atropisomerism in medicinal chemistry and how atropisomerism has transitioned from a “lurking menace” into a leverageable design strategy in order to modulate various properties of biologically active small molecules. This Account will also discuss recent advances in atroposelective synthesis, with a focus on methodologies toward pharmaceutically privileged scaffolds. We predict that a better understanding of the effects of conformational restriction about a prospective atropisomeric axis on target binding will empower chemists to rapidly “program” the selectivity of a lead molecule toward a desired target. American Chemical Society 2022-09-26 2022-10-18 /pmc/articles/PMC9583608/ /pubmed/36153960 http://dx.doi.org/10.1021/acs.accounts.2c00500 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Basilaia, Mariami
Chen, Matthew H.
Secka, Jim
Gustafson, Jeffrey L.
Atropisomerism in the Pharmaceutically Relevant Realm
title Atropisomerism in the Pharmaceutically Relevant Realm
title_full Atropisomerism in the Pharmaceutically Relevant Realm
title_fullStr Atropisomerism in the Pharmaceutically Relevant Realm
title_full_unstemmed Atropisomerism in the Pharmaceutically Relevant Realm
title_short Atropisomerism in the Pharmaceutically Relevant Realm
title_sort atropisomerism in the pharmaceutically relevant realm
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583608/
https://www.ncbi.nlm.nih.gov/pubmed/36153960
http://dx.doi.org/10.1021/acs.accounts.2c00500
work_keys_str_mv AT basilaiamariami atropisomerisminthepharmaceuticallyrelevantrealm
AT chenmatthewh atropisomerisminthepharmaceuticallyrelevantrealm
AT seckajim atropisomerisminthepharmaceuticallyrelevantrealm
AT gustafsonjeffreyl atropisomerisminthepharmaceuticallyrelevantrealm